The marked improvement in survival and body weight with only marginal changes in Pex7 transcript and PEX7 protein levels from the null to the hypomorphic model should facilitate the efficacy of any future molecular therapies in RCDP. This evidence concerns the gene PEX7 and rhizomelic chondrodysplasia punctata.